Quick orientationEvidence update: 6 October 2026
What is Cagrilintide?
Cagrilintide works on a different appetite system from the famous GLP-1 drugs. It is a long-acting analogue of amylin, a hormone normally released alongside insulin after you eat.
Why people are interested
The potential benefits, unpacked.
Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.
The headline interest
Human obesity trials, including combination development with semaglutide.
What the mechanism suggests
Long-acting amylin analogue acting through amylin receptors to increase satiety and reduce food intake.
What still needs proving
The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.
What is it actually doing?
Long-acting amylin analogue acting through amylin receptors to increase satiety and reduce food intake.
The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.
Results at a glanceHuman evidence
What did the studies actually find?
Human study deep dive
The most informative human evidence we could identify is translated below, with the original source linked.
Study evidenceStudy deep dives
The important studies, translated into normal English.
Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.
Cagrilintide dose-finding Phase 2 — Lancet 2021
Randomised Phase 2 · 706 cagrilintide participants plus active/placebo controls · 26 weeksOnce-weekly cagrilintide 0.3–4.5 mg produced mean weight reductions of 6.0%–10.8%, versus 3.0% with placebo. At 4.5 mg the mean loss was 10.8%, compared with 9.0% with daily liraglutide 3 mg.
This established a dose-response human weight-loss signal for amylin agonism.
What it doesn't prove: Phase 2 duration; gastrointestinal events and injection-site reactions were common.
Read the original study / source ↗
Dosing referenceResearch, licensed & reported protocols
What doses and schedules are actually documented?
Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.
Human research / licensed or product dosing
| Protocol / context | Amount & frequency | Duration | Titration | Evidence |
|---|---|---|---|---|
| 0.3 mg arm | 0.3 mg SC weekly | 26 weeks | No escalation | Phase 2 |
| 0.6 mg arm | 0.6 mg SC weekly | 26 weeks | No escalation | Phase 2 |
| 1.2 mg arm | 0.6 mg week 0 → 1.2 mg from week 2 | 26 weeks | 2-week step | Phase 2 |
| 2.4 mg arm | 0.6 week 0 →1.2 week 2 →2.4 mg week 4+ | 26 weeks | Every 2 weeks | Phase 2 |
| 4.5 mg arm | 0.6 week 0 →1.2 week 2 →2.4 week 4 →4.5 mg week 6+ | 26 weeks | Every 2 weeks | Phase 2 |
Community / clinic / specialist protocols
| Pattern | Amount & frequency | Cycle | Progression | Status |
|---|---|---|---|---|
| Community use | Usually borrows trial-style weekly dosing; lower starts such as 0.25–0.3 mg are often discussed | Long-term | Slow escalation commonly reported | Anecdotal; distinguish standalone from CagriSema |
There is no single Phase-2 ladder: lower arms were fixed while higher arms escalated. Show the arms separately.
Evidence checked: 7 October 2026
Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.
Community reportsCommunity reports
What are people actually doing?
Community experience exists, but is anecdotal
Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.
View the discussion on Reddit ↗
Safety and uncertaintySafety, side effects & what we don't know
Investigational weight-management medicine; nausea and gastrointestinal effects are important trial findings.
Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.
QuestionsQuestions worth asking
What is the strongest evidence here?
This established a dose-response human weight-loss signal for amylin agonism.
Does a biological mechanism prove the claimed benefit?
No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.
Is the research protocol a recommended dose?
No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.
Primary sourcesStudies, sources & further reading
External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.